Newamsterdam Pharma Company N.v. · NASDAQ:NAMS

Newamsterdam Pharma — Investor Presentation (March 2024)

41 slides from Newamsterdam Pharma's investor presentation, Mar 4, 2024

1. Slide 1: NewAmsterdam Pharma

   Exhibit 99.4 I”) NewAmsterdam Pharma

2. Slide 2: ! ##$%&%’()*+,-.%/0&%&(121.’(%-2))(’13’(%1.141&2(’55&01’%&))6’01-&%’).3.121.’(’52(’55&01’74*62(* %&340.1.&%6(’0%-2))1…

   ! ##$%&%’()*+,-.%/0&%&(121.’(%-2))(’13’(%1.141&2(’55&01’%&))6’01-&%’).3.121.’(’52(’55&01’74*62(* %&340.1.&%6(’0%-2))1-&0&7&2(*%2)&’5%&340.1.&%.(2(*%121&%’0840.%9.31.’(%.( :-.3-%43-’55&06%’).3.121.’(’0%2)& :’4)97&4()2 :54)+ ;< =>?<<@ABCDDAD E&012.(%121& F&(1%.(3)49&9.(1-.%/0&%&(121.’(1-2120&(’1-.%1’0

3. Slide 3: b[#[! $cY4 YD#Y $deD> ! f#!gOg? ! #!! $%&’( )(’ *+%,-&.&/&01% /&+%/2 345 $$6&+%/+%789:7;&%&-+<+%,(

   b[#[! $cY4 YD#Y $deD> ! f#!gOg? ! #!! $%&’( )(’ *+%,-&.&/&01% /&+%/2 345 $$6&+%/+%789:7;&%&-+<+%,( )(’ *+%, 3P hgOg?\F’H-&/%’’%HQ:ijk( ,&’//+/&%&&3P hgOg?\k%++&H-&/+lmnopm qrstuvsmtwxyz{|} +&’ 3=4>?@6,’A&’ &B1%+. ~ $CC!#>DC EF:GH+%-+A+ *+-/%, ( )(’ *+%,A/<-1,-+<H-&/+&’/2 34 hgOg?\Q( 3? hgOg?\Q j) j

4. Slide 4: E@ = F #$#% $& ’( () >;6$#6/:;4 -$;9 *G,, -%./& :;6?6!#4 !:$#46!#3 WO‘POYPSOP_

   E@ = F #$#% $& ’( () >;6$#6/:;4 -$;9 *G,, -%./& :;6?6!#4 !:$#46!#3 WO‘POYPSOP_ ]SORPQOZQNOSO\NST @ 01 EH A4%8B43C ! #$# E@ PYP ¡ /2&#34!5/4$%! 36/74#8 >;6$#6/36< !/$;9 % $& ’( ()*DD -%./& 89:6;<8 &63#6; &6 -4$ ¢£⁄¥¢ƒ§ƒ§¤' :;6?6!#4 !:$#46!#3 1 “«SQ_‹ PYP QNOOSURQ\ZOSORQZ ! #$#% $& ’( () *+, -%./& E 4

5. Slide 5: yz{|}~|. ,3z~z}|z~~2+ ,+-.z}2 U VWXYZY \[ ‘abacKL [ \ \dKe K\ KL!M’K! #$ !

   yz{|}~|. ,3z~z}|z~~2+ ,+-.z}2 U VWXYZY \[ ‘abacKL [ \ \dKe K\ KL!M’K! #$ ! ae[f g \[ daac !(’’ #$ &* %&’(M&’(N) #$%&’&’&’&() (i %&’((&’(M)$hedK\\ jk8k;lmk;n;o8k;pl + ,+-./00 + ,+-./]PP+ ,+-./OP tDuvw 1234+ 1234+ 1234+ xsutw Q^JQRJHIJ qBjrs;mk;n;o8k;pl suTw C5G_89:;<=<>C5GS89:;<=<>56 789:;<=<> ?@?ABC

6. Slide 6: « „”»…‰… ~‹ ›‹ ¿”»…‰… rstuvuswxy ¿``…‰… ¿´»…‰… zu {stuvuswxy –†st‡u·¶• ˆ lqekoijk|qefekemhjh djkfongi}

   « „”»…‰… ~‹ ›‹ ¿”»…‰… rstuvuswxy ¿``…‰… ¿´»…‰… zu {stuvuswxy –†st‡u·¶• ˆ lqekoijk|qefekemhjh djkfongi} pefqlj e|migekqm ekgfiefqifl jghhjigmqmd n eqmniignojei dei|jgeigfgjki}~fqe l oe mkigqfgeqeinqekem ~fgghejq |fqfoj¡¢ £⁄¥ƒ§¤⁄''⁄¥“ ! #$%&!’(’)*+#,- .$)#!/0 . 10!2#)3#$#0! 4 ...0!*5&!’(’)*6 0()’)0)’7#

7. Slide 7: ! #$ %& ’()* +,’ - #.!/ )) #012#23.$ 4, 23.%$)’!.$%.(.&2%) 6 42#7 )$#’

   ! #$ %& ’()* +,’ - #.!/ )) #012#23.$ 4, 23.%$)’!.$%.(.&2%) 56 42#7 )$#’ -)* fg X ‘abcde mnmhb Z Y oa W X p ‘abcde W X YZ [\fg Xhijk l] ]^_ eZq\ZZ [ rsts‘uvwwpZkjxxywz{{|}~]]ij~ l]_w|v_ Yqsts‘uv]]~]}k 9:;<=>?9@ ABC:D@E>FGHCIFHFHC<:;JCK=H:L><MNMO8 P:H>?QQRSGTBTIG:U><TDJH<>FH A>DHV

8. Slide 8: ijkijk ivkiukirkiqk e efgh elmnop gh stlmnop w xwyz{z|}|w xwyz{z|}| yyyw xwyz{z|}|~ yz{z|}|yz{z|}| mg

   ijkijk ivkiukirkiqk e efgh elmnop gh stlmnop w xwyz{z|}|w xwyz{z|}| yyyw xwyz{z|}|~ yz{z|}|yz{z|}| mg ~xx x em |~~~~}~ ~}~ zz¡{z¢zzz z z¢{y z z d} £|} £ } £d} £}~} £} £ |} £ƒ⁄} £§ ¤} £ ¢⁄} £¥ ' g ¤ ¤ ¤ ¤ ¤ d“«z{‹} ›z{ § ¤{“£fl n– §z«y{‹£{§z«“zfl¢ fiz{y fiz{y fiz{y ›z£z¢¡{{z{¢y{“zzy{z¢zy{z¢ † {z¢{fl ik‡z ¤

9. Slide 9: rss B; <;./=>?6230960 784/4H5 =20@3T@=::3646UP.Stu39v=624H5=1 ../0112/34560 784/31090:;<;./=>?6230946/011>3::=/=92488…

   rss B; <;./=>?6230960 784/4H5 =20@3T@=::3646UP.Stu39v=624H5=1 ../0112/34560 784/31090:;<;./=>?6230946/011>3::=/=92488/046@=1A39 BC ´946=2/483HFJ46=2/483H<456=2/483HFG=23 73H= L=M5=205D=842@4P/45?=92;=IJ30 K E E E EK E E EK E $ ª$%Æ$+$)-$-)$%*,)Æ’*$’- ! #$%&’()*+,’- ˇ¯—¯˘¯˝˚ ¯˝˘¯ ˝˘˝¯¸˘ ˆ˜¯˘˙ ¨˙¯˙˚¸¯

10. Slide 10: #$%&’()&*+$,&%-.*/0*122*%*2$1$%-&3-&0&1%)&*24%$4)&*25$ 63*-.0$10785%9*/-&09/%0 6*:2.;;&-;-$ 6&<3&5%*%.$107 ! =$9-5&0’…

    #$%&’()&*+$,&%-.*/0*122*%*2$1$%-&3-&0&1%)&*24%$4)&*25$ 63*-.0$10785%9*/-&09/%0 6*:2.;;&-;-$ 6&<3&5%*%.$107 ! =$9-5&0’>?@*-%&-&%*/7#AB C7DEEFGH?=5)I*-%J&%*/7#AB C7DEKDGL?M.15$;;&%*/7#AB C7DEKFN?@$I 6*1&%*/7#AB C7DEKFO?P$ 63*1:Q*%*

11. Slide 11: INK IJKIMKIPKIQK LO R LRSTUVWXWXWZ[W YUW [\W[VW]\W^VW_XW L]V ‘a ]VV ‘a VV ‘a VV

    INK IJKIMKIPKIQK LO R LRSTUVWXWXWZ[W YUW [\W[VW]\W^VW_XW L]V ‘a ]VV ‘a VV ‘a VV ‘a V ‘a bTcdefg fg fg fg Ocdefg fg fg fg RIK hijkjg lj ijkjg lj UVYU\WUVYU\WZXY\XW Ob hVWfgjd\W^WU\ WY[\W m noomLpo qrss tur fvwxyz{Y |t w} |ux~v}}xsxvwxxxvsxvrs \V]X\^XUV_U[VZZ__VVVddd bR LRSIKX_XX]Z^]V\ddd R LRSTIKUVf~

12. Slide 12: 6$7898:;&)<)=+.>)?1@2 #$ %&’()*+,-./01+*2 HEEA EB ! HEaA ! aABHCD ! ! 645 6 b

    345 6$7898:;&)<)=+.>)?1@2 #$ %&’()*+,-./01+*2 HEEA EB ! HEaA ! aABHCD ! ! 645 6 b IJIK LMNKOPQRPSTUVQWT MU[RZPJ \T] ^J]TZSG XYZTWQIT _JIK LMNKOWJ \TUQIR‘ %4 A B EF B AB EFB 0>c? 0>c? G !fde ff ! CD ! 45 hlm{ki~jli~ljjhoholk~k~ki~h ghijklmnolpqgrsnt utvvwxyzy{|}h~~hjljhiy~ ulrm ghijklmkoh~~gjko ul~ll

13. Slide 13: P Q) *+) *+, #$%%&#’( ! RSTUVWXWYRSZTUVWXWYRS[\UVWXWYRS[\UVWXWYRS[ RSUVWXWYRS]UVWXWY ^V_‘Xabc ^VXa -./01234. 56789:7;…

    P Q) *+) *+, #$%%&#’( ! RSTUVWXWYRSZTUVWXWYRS[\UVWXWYRS[\UVWXWYRS[ RSUVWXWYRS]UVWXWY ^V_‘Xabc ^VXa -./01234. 56789:7;7<.0.=>12;076>=?@ 5A 5.8.;B20769CD..E2::7;7>81E/:2FGHIJDCKL-MCKL-MNC78:O7678DB7F2N:7;7F2;F

14. Slide 14: ˇ0/i0$i$j/ 0i/Æ .$ #/jj$ªfj!# ff fffff%ffffff k=Q=k=Q=k=Q=k=Q=k=Q= ! #$%&’ () *+),-./ 0 12324 567689:4;˚¸´˙¨

    ˇ0/i0$i$j/ 0i/Æ 0 .$ #/jj$ªfj!# ff fffff%ffffff k=Q=k=Q=k=Q=k=Q=k=Q= ! #$%&’ () *+),-./ 0 12324 567689:4;˚¸´˙¨ < =>? =6@A8BCDE1 D1FGHII JKLMNO fi–fi 7PQRSTQU ƒ⁄ ‹‹ ˚¸¸`˙¨ ! #$%&’ ((VW, X-./ 0 12324 567689:4; < =>? =E1 D1FGHYZ JKLMNO[\]I^_ (g/$. i/g § ˇj!$. i— ˙˚ˆ˘¸¿ ƒ⁄ ! #$%‘a (- ’ba)cW-./ 0 . ‹‹ <A8B

15. Slide 15: ! # #$ %& %’ ( lkirtz||¡z¢|¢}£| )* +, *-./+0+123340526 781240980:;46 <* = >621+628;?@13A>B20238B

    ! # #$ %& %’ ( lkirtz||¡z¢|¢}£| )* +, *-./+0+123340526 781240980:;46 <* = >621+628;?@13A>B20238B C+1 D46E9 ⁄¥ #$ƒ§¥¥’ yz{|}~ 80:;46F2 740G644 7+3621+628 )c$ƒ¤¥¥’ )HI J45K812+01L40 *F )% &% ghijklmnoihp qrstuvwx )'“«‹›fifl )I JF18120M014B+6801 )–† )F18-B+B2K2:B4 D+620/1A+68K2+L D21A80 yz{|}~ ddBB8833++

16. Slide 16: ! # ! $ %& %’() * +,-.,/,012340.56 7898:;,1<=5..3234>?2021@,0/ABBA C0D ¡¢£⁄¥ƒ¥¢§¥¤ƒ¤'¥¥ E+,-.,/,012340.56 7898:FGHH I…

    ! # ! $ %& %’() * +,-.,/,012340.56 7898:;,1<=5..3234>?2021@,0/ABBA C0D ¡¢£⁄¥ƒ¥¢§¥¤ƒ¤'¥¥ E+,-.,/,012340.56 7898:FGHH IJKLMNGOPQ IIRSKMTURVOWW 74XY8>Z[\ 77ABX8@ ]^3A3:+98:FG_H IJKLMNG‘P‘ IIRSKMTUR Zab 74XY8>Zc[ 77ABX8@ C21d,1B.,01c520e.3d,3=.50 ]^ E+,-.,/,012340.56 7898:FGOWW IJKLMNG‘Pf IIRSKMT ghiRi:

17. Slide 17: CB----- ?- ¡¢£££ 8+9:);’(<=> ⁄¥ƒ§¤'“«‹›fifl–†‡'·‡¤“ †¶' †ƒƒ• ! #$%?@ ‡“ƒ·‚†‡·„¤‡†‡'¤ ”'‡»‚'¤…·»†¥·‚¤†„ &’() AB>C ‰

    CB----- ?- ¡¢£££ 8+9:);’(<=> ⁄¥ƒ§¤'“«‹›fifl–†‡'·‡¤“ †¶' †ƒƒ• ! #$%?@ ‡“ƒ·‚†‡·„¤‡†‡'¤ ”'‡»‚'¤…·»†¥·‚¤†„ &’() AB>C ‰ ‰fi¿ `´„ƒ *++,--,D ˆ'' §˜“ƒƒ“ ”§–¯˘•·†‚¤./00 123 4% 5!6!7%5 h˙–“'‡ ˆ‹fi¨ --˚–“'‡ ˆ‹fi¨ ?DD? E !% F 1 5$ 4G/G%! HIIJKJLHMJ A hi++ -D- &’() fi“¸·‚¤'““˜–‚·„'†·‡·¤‡“„'†·‡·¤-N *++-N? ‹¥ƒ·¸·ƒ¤'„'†·

18. Slide 18: # # ; $%*+-./0/1232456/ 7689:$ ! & !’ ’ ()’ , &< ( ?

    # # ; $%*+-./0/1232456/ 7689:$ ! & !’ ’ ()’ , &< ( ? # # #?#\ >< ( ! ’ ()’ *’ !(% ]< ( %=’>= * \ @ABCDEFAGCHBIAJKLFCKMNGCHBBAIJOCFCJBPI QIBLBIAJKRSHBMLPFCKMPBK QLTUIVVCFVFA QCWXCHBLBIAJKRYOCBI QIJZAVFCZMPLBAFTKMN QIKKIAJKIKKMNGCHBBALUUIBIAJLPUIKHMKKIAJK[IBOFCZMPLBAFKR

19. Slide 19: Obicetrapib for Cardiovascular Disease

    NewAmsterdam 7 /Y % Pharma , Pa Ve 1K \ Obicetrapib for Cardiovascular Disease |

20. Slide 20: ! #$% $%L !677#!7#! # =’’( ABC RRNS( C6 BC6 PPNQ( C6 B T67

    ! #$% $%L !677#!7#! # =’’( ABC RRNS( C6 BC6 PPNQ( C6 B T67 $% ABC DUU GHIJK $% M&NO( 7# $% DEF GHIJK =PNQ( 890:/;)<;3=’<;3=’>890:/;)<;3=’<;3=’>890:/;)<;3=’<;3=’> ?@/=’?@/=’?@/=’ VWXYZ[\]^__^‘ab‘[c de[a^_fgfWhc_i‘iZ^_jikilW_Wmbnonp &’ ()*)+,-./0- 1/+-20-3/+-40--0.5/-

21. Slide 21: /0 ! #!$% &% ’()*$ $ + ,-. + ,-.0 123456789 :9;<7=<5858>;?=<5=@7=@939=@9=> :5;A9;?BCDE;78A5=@5=9FG7>7=<=9HCDE@;I<>5;<…

    /0 ! #!$% &% ’()*$ $ + ,-. + ,-.0 123456789 :9;<7=<5858>;?=<5=@7=@939=@9=> :5;A9;?BCDE;78A5=@5=9FG7>7=<=9HCDE@;I<>5;<9> + ,-.0 + ,-. Q RSM RSP RSP RPxyzP PP J PP KP KP KPKP KLP KLP KLJ KJP KJP KJP KJN KMP KMP KMN KOP KOP TUVWXYZ[\]^X_U‘‘aTbcYde‘\]ed fYghihhjhkZ[lmhn[lmk\h\oe‘‘epdqpYr fcYde‘\b\Usr‘^p

22. Slide 22: :;<;=;;>? @;ABCDEFG HIJK :JLM ij?>;>kLl ! #$%&’ (&)$%*+#,)& -. (&) /01% l m<;:;no :;noL=no

    :;<;=;;>? @;ABCDEFG HIJK :JLM ij?>;>kLl ! #$%&’ (&)$%*+#,)& -. (&) /01% l m<;:;no :;noL=no q r p> 7s 97s rq97s 9 i 7 tu97 tu97 tu 9 rrq Ll 7s rr97 s r97 sq9 i 7 tu97 tu97 tu 9 Fv G 7sq97rs97rsq9 p> i 7 tu97 tu97 tu 9 FvG qq r p> BCDEF 7 sqq97s 9 Jxy FI7s9 < woDooonwoDooon m? NOPQRSTUVWWVXYZXS[ \]SYV

23. Slide 23: % &’()* +,-. /01.23-456,7689:8-;:<3-=8>9, ?@3A8BC-8D 03EFGH +,-. /01.2D ?=I41HJ,-.;983; ?8-;6,6KB3;C,-56,7D ?=I41HJ,-…

    % &’()* +,-. /01.23-456,7689:8-;:<3-=8>9, ?@3A8BC-8D 03EFGH +,-. /01.2D ?=I41HJ,-.;983; ?8-;6,6KB3;C,-56,7D ?=I41HJ,-.;983; ?8-;6,6KB3;C,- LMNOPQRSTUUTVWXVQY Z[QWTU\]\M^YU_V_PTU‘_a_bMUMcXdedf ! #$ ! #$

24. Slide 24: 5!4! 6!4!5 ! # 9: ;<==>?@A?BCBD<EFGH=?A<E? ;IE?=GJ?=KFIL?FE<DD?> G@<EF?EG<=M<==FN<@=<EO?EPAGQ?>BCBD<EFGH=?A 9RGONBCBP…

    4 5!4! 6!4!5 ! 5 # 9: ;<==>?@A?BCBD<EFGH=?A<E? ;IE?=GJ?=KFIL?FE<DD?> G@<EF?EG<=M<==FN<@=<EO?EPAGQ?>BCBD<EFGH=?A 9RGONBCBPS=?T?=AFKDGH<==KAGO@GUKFN<F<D<FG?@FN<A< # $ NGON?EDEIDIEFGI@IUA ;<==>?@A?BCBD<EFGH=?ATAV %&%’(’)*+(%’+, -(+..(/.01023 =<EO?EPAGQ?>BCBD<EFGH=?A vw v # $ %&%’(’)*+(%’+, -(+.xy -0102

25. Slide 25: ! #$!%&’#%!!%%$($! )$((* +*,$&%#(-.&! ! ,$%!% $.$(!(/$%* +*01%,% )$(,$&$ )%& 1$%!%%$8! % .9:# ).

    ! #$!%&’#%!!%%$($! )$((* +*,$&%#(-.&! ! ,$%!% 234 $.$(!(/$%* +*01%,% )$(,$&$ )%& 1$%!%%$8! % .9:# ). 7%$(* +*01 )$((* +*01 .&/%$#/,% )$(* +*01,& ( *,,&%! &$#%!$%!3,($#. .9 .;: * +*012! )(9*43<3=>?@A9B<< )$((* +*01 C3C=ACB=?9?C=A 2! )(9*4 * +*:2! )4<=D3=<93=< C=3a &’#%! ^_‘ E F&$% ,% )$( [\] * +*01 G

26. Slide 26: ! cfafcfaf 0$12! fdi‘kafd hk c Y 120X Y\9@ $ BIED Y\ Y =M=NEOENB

    ! 34 cfafcfaf 0$12! fdi‘kafd hk c 5 Y 120X Y\9@ $ BIED Y\ Y =M=NEOENB Y\[\ JPD?QEDRD@A Y [ Y YZ ;CETUDE?H@I YZ HI?@HI?EB?HIEB OHFV0W;$1C2 S YZ#[\ ] Y\[\ ] Y[] qvvnop nsv nnqrs tp tqru nvv sors 2620$ 7$82 utrv9:;<=< sv >?@AB;CDEFGB@DA?H@I v JD@ KHI?EB?HIEBL=M= %&’()*+&,-) wxyz {|}yz {|}~wxznvz~ NEOEN

27. Slide 27: HIHI F G MHNOP GQI H JKLIH JKLPRI STUTH VI WXYXZ[\]\^_ ‘abcdefgh‘acddfgh WXYXZ[ij_^\jk ldc‘gfdhlgc‘dfeh

    HIHI F G MHNOP GQI H JKLIH JKLPRI STUTH VI WXYXZ[\]\^_ ‘abcdefgh‘acddfgh WXYXZ[ij_^\jk ldc‘gfdhlgc‘dfeh WXYXZ[Zjmjij dcfhcfah STnUT oWXpYXZ[\]\^_ bcfbhlc‘fah WXpYXZ[ij_^\jk qq rj^\sZ qq t uv G WXYXZ_j^kwxy\]kwZz]x\wx{^\w]x ‘acdfbh‘aclfh ]|Z\{k}ki{y ! ! #! $%%&#&’($)*+,*-&(’# !’.&/ #!$0&.%’- $! 1-2#

28. Slide 28: ! #$$%&’%()*(+ ,-./+ ,-./01234/ ,5. 6/!0 9:$;#!%)< !# $=! !$#$% !$% ( %%*)$$;) >#%!)$/!’)%<$;

    ! #$$%&’%()*(+ ,-./+ ,-./01234/ ,5. 6/!0 778 9:$;#!%)< !# $=! !$#$% !$% ( %%*)$$;) >#%!)$/!’)%<$; )%;%) 3221 ?3 60./%))*($’% @$=!&!8AB!A9 C= !)$!$#$% ( %%!$% *)$$;)! @$$$% @’$=!&!)$!$);*%$$; /! !)$$!$);$%; /()(%!! %$)%! {$% -#$% BB 4 (% ,()*(8 = ,()*(x9 = :: 4 (% ,()*(8 = ,()*(x9 = xx 99 x x : : B B

29. Slide 29: Target biology and class overview: Key lessons learned

    SY” hom arma . ; « Ve /) ; ”~N \ Target biology and class overview: Key lessons learned

30. Slide 30: ;=U “#,#&*# #)«%)%&&$*($QR‹0* ›#$#T# #&(#T ›*)«% ’*SNO*T#T.(OS(-fifl *-$#%S#/$%)«#$)«%-flT#$#%S#5%S)«#$* ’%$+ M(P.($Q–fl$…

    ;=U “#,#&*# #)«%)%&&$*($QR‹0* ›#$#T# #&(#T ›*)«% ’*SNO*T#T.(OS(-fifl *-$#%S#/$%)«#$)«%-flT#$#%S#5%S)«#$* ’%$+ M(P.($Q–fl$*S$#TO)*(-† q ==KW nUo &#%T*-N)(*-%$($*%)#( ’(O-TS#&#)*(-($*-%$($*%)#Q– !‹T#S*N- :;?> ?;; <o ;77K rs7> ?; : @IFFBFGHCD‘BpbGIFEJ > ?>K> V :W :U v :> ?>K> V :W ?> ;Y ?7 8 8K ?;W : > ?>K

31. Slide 31: 5&/01%( )(’9: 1! %0; <;< tu ! *v wxyz{| ! } #! $% &’(

    5&/01%( )(’9: 1! %0; <;< tu ! *v wxyz{| ! } #! $% &’( )(’’~’ } } 4567 *+! 1$%0&8% * *++ ’ ’ tt<< (( )( #% } 4567 &8%0&/! *+ %.y| ! 1! %0%! / %. 9u w(+ 76/ 4 5%. %8 /!-.% +) w 0%.6 }% !-!//0 ( ,-. &/01% *+ 232! 1$%0 u) /%0 !- )w ) 4567&8% *+; ?@ABCDEFG HDBICJKLDJBMGEE@CIJMI@KNOPON QJR@CSIKICNTS@UJSLD

32. Slide 32: [\]^\_‘ abcbdefdgbhijdklbhbkdc\^mncklgbdohc pc^\d\qhj^fkbr]jsdbtfekcj_hmhljnhb]\d\kcj_^\kbdkl\_uob\dhmnlcel chklb]jc_…

    [\]^\_‘ abcbdefdgbhijdklbhbkdc\^mncklgbdohc pc^\d\qhj^fkbr]jsdbtfekcj_hmhljnhb]\d\kcj_^\kbdkl\_uob\dhmnlcel chklb]jc_kc_kc pbkl\krvvwxwyrzwhkj]]bt {| }| {|}~ }| #$%&’()%’*+%,-’.%/ 0)%1’**/2)21’34.+/3,56-/2-/37 89:;<=>7?6)(4’*/3’4)(,-’2+ 0.+(/,’+*4’),-*%+ 02)%4/+&)(2$@)%4/(’)(’5) 0)A+%2+%+3)%1’&’3,B3

33. Slide 33: #$#%’(070,-./01+*2 ! #$%&’()*+,-./01+*2 ;; YZ BM:9= <[:<= AXX CD E NOPQHRD EIS TDSIHUA FGHIJKLIC

    345 6 #$#%’(070,-./01+*2 ! #$%&’()*+,-./01+*2 ;; YZ BM:9= <[:<= AXX CD E NOPQHRD EIS TDSIHUA FGHIJKLIC NCVJD EIOKLQW> \: 89 : 89: ?: ]/)1 ]/)1 ? : A_^X __ ;<= >> bgh|kngpsovhepoge cstqfiihvivb crtdbgrhgfnsonsonposgfbmz ‘ab cdbefghebi jkalfmnopqhqfmgrfesmsotefeuhvhnbvbmsvtqhsgrw ctbnsvqfsofmisvngfbmb

34. Slide 34: Obicetrapib and Alzheimer's Disease

    NewAmsterdam /Y % Pharma ' t Ve (F ; ~ \ Obicetrapib and Alzheimer’s Disease

35. Slide 35: I J abcdceabcdce ^0E ^0G L H0_ H0‘ H0H K K I J afcdccij

    I J abcdceabcdce ^0E ^0G L H0_ H0‘ H0H K K I J afcdccij l mnnn afcdcgh ^HH G0 pp ofcdeqjroftcdicip MNO _H G0H afcdcgeafcdcjse G EH ^0 L ‘H L ^0H MNO^ XY H0 ^H HHH HGH‘HEH_H^HHHGH‘HEH_H^HH MNOX JY MNOX JY Z# $+P$’ Q,-$ $=’(5$8H [9(5=(#/,$# B5(,(;$( ?D/( ?$5, P+$ ;$=P$, Q$$5 R*A M P+$ ;$=P$, Q$$5 +# $

36. Slide 36: ! >?@ABCDEFGHIGJKLJIMFLMH NHIGJI? OPQRFLHDGHSFLT% U)%VWXVYVYVV&ZZ%’W)[\]^)_)WY([XWX >‘ab cd%e^)_%W]Z) UX]\)XVV%(YXW)[…

    ! >?@ABCDEFGHIGJKLJIMFLMH NHIGJI? OPQRFLHDGHSFLT% U)%VWXVYVYVV&ZZ%’W)[\]^)_)WY([XWX >‘ab cd%e^)_%W]Z) UX]\)XVV%(YXW)[ fYWTg% f)’‘abcX(WYhYW]iX(%’’)VZ%_[Y_^Y_(’)XV)Y_jkdg)h)gV ‘abc‘abcntZ%utvs d) f]\%[] [) U)_WYXndw ks dw kntZ%auxyzs dw kntZ%auxyus cX’{Y_V%_ k) U)_WYXY_ cX’{Y_V%_ d% f)’‘abc lmnop q‘r

37. Slide 37: G@585:HI:8:JK9 3456789:;54LM =NK4?79>7I8KI7697:?7OP?QROSQTUVWXYUZTX[\]^\WX[_‘ ab cdef gX^Th[i] jiifVZ\W\gWX]hefi[k[le…

    G@585:HI:8:JK9 3456789:;54LM =NK4?79>7I8KI7697:?7OP?QROSQTUVWXYUZTX[\]^\WX[_‘ ab cdef gX^Th[i] jiifVZ\W\gWX]hefi[k[leV_‘mnocd /0!## &#**#!#!#, (## &’(# )) 12 ! / 1’#!’ &’(#’ &)## $((# &!#, & ((##’#### - <5 =>:?8:85@ 3456789:;54 )EF )D )F ) ) ) ! # $#%# &’(#!#)#) !%# &’#*# &#**#’+#(,-!### # ***.!## A

38. Slide 38: Clinical events and exclusivity timelines

    NewAmsterdam /Y % Pharma v b y . \ Clinical events and exclusivity timelines

39. Slide 39: %&! ’(! )**+ ,-*./011234056 7898:0;</=01123405> 7898? [cd eQf OPQRRSTUQV KLACMKLACN GH ’I JH #

    %&! ’(! )**+ ,-*./011234056 7898:0;</=01123405> 7898? [cd eQf OPQRRSTUQV KLACMKLACN GH ’I JH # KLABL KLAKAWM o ’b cgO eQf P[QRRSTUQV E!b KACW@ACB ^_ ‘#$a ’b KABK KAKAW@ p>qr:s XAW@YPZ[Z\]BAWMYOP\ DEF ’ %_ WWAACCBBXACjk Eh i!EF ’ ! # %n WACBXACjk Eh i!EF ’ @ABC %EF ’ _ Dl#EF ’mm ! $ %EF ’ _ Dl#EF ’@A

40. Slide 40: =>?@ABC@DEF G?ACHFIEBI?CD?@JKE>JL>>F@A?DHMAF>ENO?JAF@J %EBKC?I COEDJFNQ%; ;#FKNCJA?I?ENQ %; ; FLRICJIENR STUUTV WXYZ[…

    =>?@ABC@DEF G?ACHFIEBI?CD?@JKE>JL>>F@A?DHMAF>ENO?JAF@J %EBKC?I COEDJFNQ%; ;#FKNCJA?I?ENQ %; ; FLRICJIENR STUUTV WXYZ[Z\]^_CNF GCEMCFLEJ?FFEP %C@B EAGC@JBKQ %; ; %# $# % , $% ,# , # , ;# $ % , % .:5.:5671 2+8 2.)5671 2+8 2<8/8<8/8 <+ 28 ! ! ! ! &’()**+-./01++ 29 29 2 34+ ‘a

41. Slide 41: NewAmsterdam Pharma

    MM” a neterden

NewAmsterdam Pharma — Investor Presentation (March 2024) on 6ix